Lynch syndrome (LS) is an autosomal inherited disease caused by mutations in DNA mismatch repair (MMR) genes. LS-associated gastric cancer, its incidence ranking first among all LS-associated gastrointestinal tumors, is different from the gastric cancer in general population, and presents the pathological features of microsatellite instability (MSI) and being sensitive to immunotherapy. With the precision of LS molecular detection and the popularization of various diagnostic technologies, LS patients and their families have an increasing demand for LS-associated gastric cancer screening, surveillance, and treatment. However, but their strategies are still unclear, and there are still many controversies. The incidence risk of LS-associated gastric cancer is high in Asian population. China, as one of the Asian countries, should strengthen the identification of LS patients and standardize management measures. Here, the authors review the relevant literature concerning the LS-associated gastric cancer in recent years, so as to provide a basis and reference for fully understanding the LS-associated gastric cancer, optimizing its prevention decision, and improving its diagnosis and treatment.